Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

Core Insights - Globus Medical, Inc. reported preliminary unaudited sales results for Q4 and full year 2024, expecting Q4 sales of approximately $657.0 million, a 6.6$2.52 billion, reflecting a 60.6% increase year-over-year [1][2] Group 1: Financial Performance - The company anticipates Q4 2024 sales of around $657.0 million, marking a 6.6$2.52 billion, which is a 60.6% increase over the previous year [1] - For 2025, the company has established revenue guidance in the range of $2.66 billion to$2.69 billion, with fully diluted non-GAAP earnings per share expected between $3.40 to$3.50 [2] Group 2: Strategic Initiatives - The merger with NuVasive is highlighted as a key factor in creating a strong sales force and product offering in the spine industry, enhancing the company's innovative capabilities [2] - The company achieved a record number of new product launches and the highest placements of Enabling Technology to date during the first full year post-merger [2] - The focus remains on product innovation, superior customer service, and operational excellence to advance patient care and drive shareholder value [2] Group 3: Future Outlook - 2025 is anticipated to be a significant year for product launches across the company's portfolio, positioning Globus Medical for sustained growth in the musculoskeletal market [2] - The company aims to build upon the successes of 2024 to further solidify its foundation for accelerated growth [2]